Cubist Systematic Strategies, LLC Arbutus Biopharma Corp Transaction History

Cubist Systematic Strategies, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.69 - $2.54 $12,154 - $18,267	7,192 New	7,192 $17,000
Q1 2023 May 15, 2023	BUY	$2.23 - $3.1 $265,800 - $369,498	119,193 New	119,193 $361,000
Q3 2022 Nov 14, 2022	SELL	$1.88 - $2.88 $56,439 - $86,460	-30,021 Reduced 73.68%	10,726 $20,000
Q2 2022 Aug 15, 2022	SELL	$1.98 - $3.17 $306,339 - $490,452	-154,717 Reduced 79.15%	40,747 $110,000
Q1 2022 May 16, 2022	SELL	$2.42 - $3.98 $164,860 - $271,133	-68,124 Reduced 25.84%	195,464 $582,000

Q4 2021 Feb 14, 2022	BUY	$3.11 - $4.61 $777,462 - $1.15 Million	249,988 Added 1838.15%	263,588 $1.03 Million
Q3 2021 Nov 15, 2021	SELL	$2.65 - $4.62 $132,765 - $231,462	-50,100 Reduced 78.65%	13,600 $58,000
Q2 2021 Aug 16, 2021	SELL	$2.5 - $3.51 $304,537 - $427,570	-121,815 Reduced 65.66%	63,700 $193,000
Q1 2021 May 17, 2021	BUY	$3.14 - $4.84 $422,694 - $651,541	134,616 Added 264.48%	185,515 $618,000
Q4 2020 Feb 16, 2021	BUY	$2.76 - $4.97 $140,481 - $252,968	50,899 New	50,899 $181,000
Q3 2020 Nov 16, 2020	SELL	$1.75 - $6.2 $21,983 - $77,884	-12,562 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$0.91 - $2.36 $11,431 - $29,646	12,562 New	12,562 $23,000
Q1 2020 May 15, 2020	SELL	$1.01 - $3.42 $903 - $3,060	-895 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$0.87 - $2.89 $778 - $2,586	895 New	895 $2,000
Q4 2017 Feb 14, 2018	SELL	$4.45 - $7.7 $1,335 - $2,310	-300 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$3.4 - $7.0 $1,020 - $2,100	300	300 $2,000

130

82.2M

4.82M

546K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $468M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.